Eversept Partners LP boosted its holdings in Heska Corp (NASDAQ:HSKA) by 422.8% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 34,924 shares of the medical research company’s stock after purchasing an additional 28,244 shares during the quarter. Heska accounts for approximately 0.8% of Eversept Partners LP’s investment portfolio, making the stock its 26th largest holding. Eversept Partners LP’s holdings in Heska were worth $2,974,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Conestoga Capital Advisors LLC raised its holdings in Heska by 26.2% in the second quarter. Conestoga Capital Advisors LLC now owns 3,395 shares of the medical research company’s stock valued at $289,000 after buying an additional 705 shares during the period. Grandeur Peak Global Advisors LLC purchased a new position in Heska in the second quarter valued at approximately $6,362,000. Manchester Capital Management LLC raised its holdings in Heska by 128.6% in the first quarter. Manchester Capital Management LLC now owns 400 shares of the medical research company’s stock valued at $34,000 after buying an additional 225 shares during the period. New York State Common Retirement Fund raised its holdings in Heska by 159.4% in the first quarter. New York State Common Retirement Fund now owns 17,121 shares of the medical research company’s stock valued at $1,457,000 after buying an additional 10,521 shares during the period. Finally, Granite Investment Partners LLC raised its holdings in Heska by 2.4% in the second quarter. Granite Investment Partners LLC now owns 167,155 shares of the medical research company’s stock valued at $14,237,000 after buying an additional 3,888 shares during the period. Hedge funds and other institutional investors own 89.02% of the company’s stock.
NASDAQ:HSKA traded down $1.23 during trading hours on Friday, hitting $62.94. The stock had a trading volume of 32,944 shares, compared to its average volume of 53,486. The company has a current ratio of 3.93, a quick ratio of 2.05 and a debt-to-equity ratio of 0.04. Heska Corp has a 1-year low of $63.41 and a 1-year high of $114.50. The business has a 50 day simple moving average of $73.92 and a two-hundred day simple moving average of $78.20. The company has a market cap of $543.97 million, a PE ratio of 44.32 and a beta of 1.07.
Heska (NASDAQ:HSKA) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.04. Heska had a net margin of 1.93% and a return on equity of 6.35%. The company had revenue of $28.15 million during the quarter, compared to the consensus estimate of $29.19 million. Research analysts expect that Heska Corp will post 0.05 EPS for the current fiscal year.
Several analysts have issued reports on the stock. ValuEngine raised shares of Heska from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Canaccord Genuity reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Heska in a research report on Thursday. BidaskClub downgraded shares of Heska from a “hold” rating to a “sell” rating in a research report on Saturday, August 31st. Finally, Guggenheim assumed coverage on shares of Heska in a research report on Thursday, May 23rd. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $91.00.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Read More: Do closed-end mutual funds pay dividends?
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.